Q-omics provides the consensus-scored RPL12P6 profile across patient tissues and cancer cell-line models. RPL12P6 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, RPL12P6 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, RPL12P6 RNA expression shows 6,534 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight LUSC, KIRC, and DLBC as cancer lineages where RPL12P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL12P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL12P6 survival associations across molecular data types. RPL12P6 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL12P6 RNA expression–survival associations across cancer types. High RPL12P6 expression shows unfavorable associations in OV, COAD, ACC and LUAD, but favorable associations in LUSC and MESO. The LUSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify LUSC as the clearest survival context for RPL12P6 RNA expression.
This table summarizes RPL12P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL12P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL12P6 shows higher tumor expression in KIRC, THCA, COAD, HNSC, LUAD and KIRP. The KIRC box plot shows higher RPL12P6 RNA expression in tumor versus normal tissue (log2 FC = +0.165, t-test p < 0.001).
This table shows molecular features associated with RPL12P6 in patient tissues and cancer cell lines. In patient samples, RPL12P6 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
